Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/11092
|
| Title: | Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection |
| Authors: | Yang, HC;Tsou, HH;Pei, SN;Chang, CS;Chen, JH;Yao, M;Lin, SJ;Lin, J;Yuan, Q;Xia, N;Liu, TW;Chen, PJ;Cheng, AL;Hsu, C;Taiwan Cooperative Oncology Group |
| Contributors: | Institute of Population Health Sciences;National Institute of Cancer Research |
| Abstract: | BACKGROUND AND AIMS: Absence or low anti-hepatitis B (HBV) surface antibody (anti-HBs) is associated with increased risk of HBV reactivation in lymphoma patients with resolved HBV infection receiving rituximab-containing chemotherapy. Quantification of anti-HBV core antibody (anti-HBc) is a new marker associated with the natural history and treatment response of chronic HBV infection. This study investigated whether baseline anti-HBc and anti-HBs levels may better predict HBV reactivation. METHODS: We prospectively measured the HBV DNA levels of lymphoma patients with resolved HBV infection receiving rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-based chemotherapy and started antiviral therapy upon HBV reactivation, defined as a greater than 10-fold increase in HBV DNA compared with previous nadir levels. Anti-HBs and anti-HBc were quantified by a double-sandwich assay. Receiver operating characteristic curve analysis was used to determine optimal baseline anti-HBc/ anti-HBs levels for predicting HBV reactivation. RESULTS: HBV reactivation occurred to 24 of the 197 patients enrolled, with an incidence of 11.6 per 100 person-year. For the 192 patients with enough serum samples for analysis, low anti-HBs (<56.48 mIU/mL) and high anti-HBc (>=6.41 IU/mL) at baseline were significantly associated with high risk of HBV reactivation (hazard ratio (HR) 8.48 and 4.52, respectively, p<0.01). Multivariate analysis indicated that (1) patients with both high anti-HBc and low anti-HBs at baseline (36 of 192 patients) had a HR of 17.29 for HBV reactivation (95% confidence interval (95% C.I.) 3.92-76.30, p<0.001); (2) HBV reactivation may be associated with inferior overall survival (HR 2.41, 95% C.I. 1.15-5.05, p=0.02). CONCLUSIONS: Baseline anti-HBc/ anti-HBs levels may predict HBV reactivation in these lymphoma patients and help optimize prophylactic antiviral therapy for the high-risk patients. LAY SUMMARY: In this study we identified a subgroup of patients with lymphoma and resolved HBV infection who had high risk of HBV reactivation after receiving rituximab-containing chemotherapy. These findings will help optimize preventive strategy, especially in HBV-endemic regions with limited health resources. |
| Date: | 2018-08 |
| Relation: | Journal of Hepatology. 2018 Aug;69(2):286-292. |
| Link to: | http://dx.doi.org/10.1016/j.jhep.2018.02.033 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0168-8278&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000438753600006 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85046163058 |
| Appears in Collections: | [鄒小蕙] 期刊論文
[劉滄梧] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB29551710.pdf | | 2277Kb | Adobe PDF | 369 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
